Benzbromarone Therapy in Hyperuricaemia

Abstract

A series of patients with hyperuricaemia associated with rheumatic symptoms were treated with Benzbromarone (Minuric®) and followed over a period of 5 months. Each patient was assessed clinically and biochemically before and at regular monthly intervals during the trial.

All patients showed a marked reduction in serum uric acid levels and a significant increase in urinary uric acid elimination rates. Some degree of clinical improvement was noted in most patients and the drug was well tolerated throughout the study. Two patients were withdrawn during the trial; one because of diarrhoea, probably due to benzbromarone and the other because of lack of efficacy.